Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold.
Zeidler HK, Kvien TK, Hannonen P, Wollheim FA, Forre O, Geidel H, Hafstrom I, Kaltwasser JP, Leirisalo-Repo M, Manger B, Laasonen L, Markert ER, Prestele H, Kurki P.
Medizinische Hochschule Hannover, Division of Rheumatology, Germany.
Br J Rheumatol. 1998 Aug;37(8):874-82.
online abrufbar
Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension.
Kvien TK, Zeidler HK, Hannonen P, Wollheim FA, Forre O, Hafstrom I, Kaltwasser JP, Leirisalo-Repo M, Manger B, Laasonen L, Prestele H, Kurki P.
Oslo City Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. t.k.kvien(at)ioks.uio.no
Ann Rheum Dis. 2002 Jun;61(6):511-6.
online abrufbar
Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study.
Drosos AA, Voulgari PV, Katsaraki A, Zikou AK.
Department of Internal Medicine, Medical School, University of Ioannina, Greece. Rheumatol Int. 2000;19(3):113-8.
online abrufbar
Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A.
Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M, Marcolongo R, Oriente P, Pipitone V, Portioli I, Tirri G, Trotta F, Della Casa-Alberighi O.
Milan University, Italy.
Arthritis Rheum. 1996 Jun;39(6):1006-15.
online abrufbar